๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Ardelyx, Inc. (ARDX)
NASDAQ: ARDX ยท Real-Time Price ยท USD
3.060
-0.060 (-1.92%)
At close: Nov 19, 2026, 4:00 PM EST
3.050
-0.010 (-0.33%)
After-hours: Nov 19, 2026, 7:30 PM EST

Ardelyx Earnings Call Transcripts

Fiscal Year 2026

Fiscal Year 2025

  • Delivered 22% revenue growth in 2025, driven by IBSRELA's 73% increase and XPHOZAH's resilience despite Medicare changes. 2026 guidance projects strong double-digit growth, with robust cash reserves and pipeline expansion supporting long-term targets.

  • The company highlighted strong growth in its IBSRELA and XPHOZAH franchises, driven by expanded sales efforts and high patient satisfaction. Guidance points to significant revenue potential, with profitability targeted for 2026 and a robust pipeline advancing.

  • Conference discussions highlighted XPHOZAH's real-world effectiveness, manageable side effects, and strong physician interest. Market access remains dynamic due to regulatory changes, while pipeline expansion and organizational improvements support future growth.

  • Q3 2025 saw 12% revenue growth year-over-year, led by IBSRELA's 92% surge and XPHOZAH's 9% sequential gain. Raised full-year IBSRELA guidance to $270โ€“$275 million and advanced a new NHE3 inhibitor into development, supported by a strong cash position.

  • IBSRELA and XPHOZAH are driving strong revenue growth, supported by expanded sales efforts and novel mechanisms addressing large unmet needs. Legal proceedings and regulatory changes may impact XPHOZAHโ€™s Medicare coverage, while ongoing innovation and market access initiatives are expected to sustain momentum.

  • Revenue guidance for IBSRELA was raised to $250โ€“$260 million, with a $1 billion peak target, while XPHOZAH aims for $750 million peak sales after a strategic relaunch. Commercial execution, expanded sales force, and improved patient access are driving growth, with the company nearing cash flow break-even and exploring new business development opportunities.

  • Revenue growth for IBSRELA and XPHOZAH is driven by expanded sales efforts, strong market demand, and improved patient access. The company is well-capitalized, nearing profitability, and actively building its pipeline through internal research and external opportunities.

  • Ibsrela and Xphozah are driving strong prescription growth, with Ibsrela targeting a $1 billion sales goal and Xphozah aiming for $750 million, supported by expanded sales efforts and digital engagement. Ongoing legal and regulatory developments, as well as real-world evidence studies, may provide additional upside.

  • Q2 2025 revenue rose 33% year-over-year to $97.7 million, led by IBSRELA and XPHOZAH growth. IBSRELA net sales surged 84% to $65 million, while XPHOZAH delivered $25 million despite Medicare loss. Full-year IBSRELA guidance was raised to $250โ€“$260 million.

  • IBSRELA continues strong growth with reaffirmed 2024 guidance and a $1B peak sales target, while XPHOZAH faces reimbursement challenges but maintains a $750M peak goal. Expansion into adjacent indications and ongoing legal appeals could further boost market potential.

  • Q1 2025 revenue grew 61% year-over-year to $74.1 million, led by strong IBSRELA and XPHOZAH sales. IBSRELA net sales rose 57% to $44.4 million, while XPHOZAH grew 30% excluding a one-time reserve release. Guidance for IBSRELA was reaffirmed, with XPHOZAH's outlook pending market stabilization.

  • Management outlined strong commercial growth for IBSRELA and XPHOZAH, with ambitious market share and revenue targets. Strategic focus includes expanding the pipeline, maintaining financial discipline, and leveraging global partnerships, while adapting to reimbursement changes and unmet patient needs.

  • Two commercial drugs, IBSRELA and XPHOZAH, drove over $319 million in 2024 sales, with strong launches and ambitious peak sales targets. Strategic focus is on commercial execution, expanding patient access, and leveraging a robust cash position to explore pipeline and business development opportunities.

  • Strong revenue growth from IBSRELA and XPHOZAH, robust cash reserves, and international expansion underpin a positive outlook. The company is navigating reimbursement changes for XPHOZAH while maintaining patient access and focusing on pipeline growth and strategic business development.

  • Strong revenue growth was driven by expanded sales efforts and innovative therapies addressing unmet needs in IBS-C and dialysis. Strategic priorities include sustaining commercial momentum, expanding internationally, and building a robust pipeline for long-term growth.

Fiscal Year 2024

Fiscal Year 2023

Fiscal Year 2022

Fiscal Year 2021